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Abstract 
Background 
Generic atypical antipsychotic drugs offer health authorities opportunities for considerable 
savings. However, schizophrenia and bipolar disorders are complex diseases that require 
tailored treatments. Consequently, generally there have been limited demand-side measures 
by health authorities to encourage the preferential prescribing of generics. This is unlike the 
situation with hypertension, hypercholaesterolaemia or acid-related stomach disorders. 
The objectives of this study were to compare the effect of the limited demand-side measures 
in Western European countries and regions on the subsequent prescribing of risperidone 
following generics; to utilise the findings to provide future guidance to health authorities; and 
where possible, to investigate the utilisation of generic versus originator risperidone and the 
prices for generic risperidone. 
Methods 
Principally, this was a segmented regression analysis of retrospective time-series data of the 
effect of the various initiatives in Belgium, Ireland, Scotland and Sweden following the 
introduction of generic risperidone. The study included patients prescribed at least one 
atypical antipsychotic drug up to 20 months before and up to 20 months after generic 
risperidone. In addition, retrospective observational studies were carried out in Austria and 
Spain (Catalonia) from 2005 to 2011 as well as one English primary care organisation (Bury 
Primary Care Trust (PCT)). 
Results 
There was a consistent steady reduction in risperidone as a percentage of total selected 
atypical antipsychotic utilisation following generics. A similar pattern was seen in Austria 
and Spain, with stable utilisation in one English PCT. However, there was considerable 
variation in the utilisation of generic risperidone, ranging from 98% of total risperidone in 
Scotland to only 14% in Ireland. Similarly, the price of generic risperidone varied 
considerably. In Scotland, generic risperidone was only 16% of pre-patent loss prices versus 
72% in Ireland. 
Conclusion 
Consistent findings of no increased prescribing of risperidone post generics with limited 
specific demand-side measures suggests no ‘spillover’ effect from one class to another 
encouraging the preferential prescribing of generic atypical antipsychotic drugs. This is 
exacerbated by the complexity of the disease area and differences in the side-effects between 
treatments. There appeared to be no clinical issues with generic risperidone, and prices 
inversely reflected measures to enhance their utilisation. 
Keywords 
Generics, Antipsychotics, Risperidone, Demand-side measures, Drug utilisation, Cross 
national study 
Background 
Health authorities across Europe are increasingly struggling to fund growing drug volumes 
and their associated costs within available resources, as a result of ageing populations and 
new premium-priced drugs [1,2]. This is already resulting in some countries no longer 
funding new premium-priced drugs, which is not in the best interest of any stakeholder group 
[1-5]. Improved knowledge of pharmacogenomics, leading to improved management of 
patients with improved targeting of treatments, is one way forward. However, there is a still 
an appreciable number of challenges to address before such approaches become routine [3]. 
In the meantime, there are considerable opportunities for authorities across Europe to realise 
appreciable savings from the increased use of low-cost generics [1]. The availability of 
generic risperidone provides a further opportunity for authorities to achieve considerable 
savings. This is because worldwide sales of atypical antipsychotic drugs were over $US 5 
billion per year in the early 2000s, reaching $14.6bn in the US alone in 2009 [6,7]. In 
addition, medicine costs can be an appreciable component of the overall cost of treating 
patients with schizophrenia, as pharmacological treatments represent the backbone of 
managing these patients [8-11]. 
We acknowledge that there is continuing debate about the relative merits of atypical versus 
typical antipsychotics in the management of patients with schizophrenia [12-16]. Recent 
studies have suggested that pharmacological treatments should be tailored, in view of the 
considerable variation in their effectiveness between individual patients [12,17-20]. In 
addition, there are also considerable differences in side-effects between the different atypical 
antipsychotic drugs, including weight gain, hyperlipidaemia and type 2 diabetes [12,17,19]. 
The risk of QT prolongation and subsequent arrhythmia-related events, i.e. torsade de pointes 
(TdP) and sudden cardiac death, has also become increasingly important [21,22]. Previously, 
atypical antipsychotic drugs were generally perceived as having a more favourable safety 
profile in terms of cardiac and extrapyramidal side-effects. However, this is changing, with 
post-marketing studies and meta-analyses challenging the definition of typical (first 
generation) or atypical (second generation) antipsychotic drugs [18,23-27]. Recent studies 
have also shown that the risk of mortality in patients with schizophrenia is highest with 
quetiapine and lowest with clozapine [28]. However, there have been concerns regarding 
patient selection in this cohort study. Haloperidol and risperidone had slightly lower adjusted 
hazard ratios than quetiapine [28]. 
However, other authors believe the modest health gains achieved with atypical antipsychotic 
drugs reported in the literature do not adequately reflect the improvement in the quality of life 
perceived by patients, clinicians or carers [29]. This has resulted in the increasing use of these 
drugs in recent years, which is likely to continue despite safety concerns [30-37]. 
As a result, the introduction of generic atypical antipsychotic drugs should be welcomed by 
European authorities in order to save costs. However, it is recognised by health authorities 
that schizophrenia and bipolar disorders are complex diseases to treat compared with 
hypercholesterolaemia, hypertension or acid-related stomach disorders, for instance. In 
addition, atypical antipsychotic drugs cannot be considered as a single class, because of the 
heterogeneity of their pharmacological activities. This is unlike the situation for proton pump 
inhibitors (PPIs), renin-angiotensin inhibitor drugs or statins [1,38-45]. In view of this, as 
mentioned, there is a greater need to tailor treatments to individual patients. This complexity 
has resulted in limited demand-side initiatives by national and regional health authorities 
across Europe to preferentially encourage the prescribing of oral risperidone versus patented 
atypical antipsychotic drugs once generic risperidone became available [46-48]. Limited 
measures included physician prescribing quotas for low-cost medicines in Belgium, advice to 
psychiatrists to consider preferentially starting patients on generic atypical antipsychotic 
drugs where pertinent in Scotland, and prescribing restrictions for long-acting risperidone 
injections in Austria and Belgium [46-48]. 
Consequently, the principal objective of this study was to compare and contrast the effect of 
the limited demand-side measures instigated by Western European countries and regions to 
enhance the prescribing of risperidone versus patented atypical antipsychotic drugs once oral 
generic risperidone became available. A secondary objective was to utilise the findings to 
provide guidance to health authorities regarding potential measures they could consider to 
enhance the prescribing of generic atypical antipsychotic drugs if this is practical and 
feasible. This is because we would expect to see limited change in the utilisation of 
risperidone following generics with limited demand-side measures and the recognised need to 
tailor pharmacotherapy. This builds on previous findings across a range of classes, including 
antidepressants, PPIs, renin-angiotensin inhibitor drugs and statins [1,38-41,47,49,50]. We 
also investigated the utilisation of generic versus originator risperidone because a universally 
low utilisation of generic risperidone would represent concerns with generics among either 
patients or physicians, or both. Finally, we investigated prices for generic risperidone versus 
pre-patent loss prices to provide guidance to countries that still have high prices for generics. 
Only Western European countries and regions were chosen for analysis as generic atypical 
antipsychotic drugs have been available for a longer time in Central and Eastern European 
countries [6]. 
Methods 
We principally undertook a segmented regression analysis of retrospective time-series 
analysis to assess the effect of various initiatives in Belgium, Ireland, Scotland and Sweden 
following the introduction of generic risperidone [51]. The xtmixed command in Stata 
(version 12) (StataCorp, College Station, Texas, USA) was used to fit a linear random 
coefficient model with country-specific intercepts. At the time of introduction of generic 
risperidone into each country, a random shift in intercepts and slopes was allowed to estimate 
the effect of the introduction. Data on the number of monthly reimbursed prescriptions within 
each country’s health service for all patients prescribed at least one atypical antipsychotic 
drug (N05AH03 to 06, N05AL05, N05AX08, N05AX011 to 13) [52] up to 20 months before 
and up to 20 months after the availability of generic risperidone was included. Clozapine was 
not included in the analysis as it is generally reserved for patients not responding to other 
atypical antipsychotic drugs because of its side-effect profile [46,53-55]. Ziprasidone 
(N05AE04) was also not included. This was in view of its different classification and limited 
utilisation in practice in a number of European countries, including Sweden [56]. 
A retrospective observational study of the same population dispensed at least one atypical 
antipsychotic drug was also undertaken in Austria and one of the regions in Spain (Catalonia) 
from January 2005 (Austria) or January 2006 (Spain) to the end of 2010 (Austria) and 
September 2011 (Spain). This was because generic risperidone was already available in 
Austria and Spain in July 2004 and by January 2006 respectively;, but only became available 
later in the four chosen European countries: Ireland in December 2007, Scotland in April 
2008, and Belgium and Sweden in January 2009. A retrospective observational study was 
also undertaken in one English primary care organisation, Bury Primary Care Trust (PCT), 
between November 2009 and October 2011. The objective was to assess the influence of a 
request to psychiatrists to consider oral risperidone as first line treatment in new or other 
suitable patients, where appropriate, now it was available as a generic. 
Finally, retrospective observational studies were undertaken on the utilisation of long-acting 
risperidone injections versus total risperidone (N05AX08) [52], which was available 
throughout the study period, as well as paliperidone (N05AX13) before and after the 
availability of generic oral risperidone. 
The European countries chosen provide a range of differences in geographical location, 
population size, different approaches to the financing of health care, and different approaches 
to the pricing of generics and to enhancing the utilisation of generics versus originators 
[39,40], which is in line with recommended guidance [57]. 
Only administrative databases were used in each country to assess the utilisation and 
expenditure patterns of the atypical antipsychotic drugs. This is because the perspective of the 
study was that of health authorities, and they typically have the greatest knowledge 
concerning existing and planned initiatives and reforms in their countries. The databases, 
which are regularly audited, are included in Box 1. Box 1 also contains details of patients 
included within the national health service of each country. This typically includes 100% or 
close to 100% of the population unless stated (Ireland), given the principles of equity and 
solidarity within European healthcare systems. There are also typically limited patient co-
payments. 
The utilisation of the different atypical antipsychotics was calculated in terms of defined 
daily dose (DDD), which is defined as ‘the average maintenance dose of a drug when used in 
its major indication in adults’, as this measure is recognised as the international standard to 
assess utilisation patterns within and between countries [58]. The only exception was Bury 
PCT, where utilisation was measured in terms of prescription items, which is the typical 
metric used to assess utilisation patterns in England [59]. 2011 DDDs were used in line with 
international guidance [58,60,61]. 
Separate retrospective observational studies were conducted in Belgium, Scotland and 
Sweden, again using an interrupted time-series methodology. The objective was to assess 
whether the changes in risperidone utilisation patterns after the introduction generic 
risperidone in these three countries were significant [46,48,56]. 
Subsequently, risperidone utilisation in Belgium, Ireland, Scotland and Sweden was 
converted into a percentage of total selected atypical antipsychotic utilisation (DDD basis) 
before and after the availability of generic risperidone (time 0). The objective was to enable 
meaningful comparisons between the four countries, factoring in differences in population 
sizes, time when generic risperidone became available, and differences in their database 
characteristics (Box 1). Utilisation patterns and calculations were verified with the relevant 
co-authors to enhance the robustness of the study findings. 
The percentage of oral risperidone dispensed as generics was also calculated in Belgium, 
Ireland, Scotland and Sweden. We would expect to see considerable differences in utilisation 
rates between countries in view of the different policies in each country regarding 
encouraging the utilisation of generics versus originators [39,40,62-65]. However as 
mentioned, a universally low utilisation of generic risperidone would reflect general 
stakeholder concerns with generic risperidone. 
The percentage reduction in expenditure per DDD for oral generic risperidone versus pre-
patent loss originator prices was also calculated in Belgium, Ireland, Scotland and Sweden. 
We chose to compare relative reductions rather than actual prices for generic risperidone as 
the price components can vary in each country (for example, there are variations in the extent 
of VAT and relative wholesaler margins ), and this approach also avoids currency 
conversions, both of which can make cross-country price comparisons difficult, especially 
during times of economic difficulty. In addition, prices of initial or all generics in an 
appreciable number of European countries are based on pre-patent loss prices 
[39,40,62,64,65], and the time periods for the availability of generic risperidone varied 
considerably between the countries and regions studied. We also did not factor inflation into 
the calculations because the trend in most European countries is to reduce prices when 
pharmaceutical expenditure exceeds target budgets [39,66] and, as mentioned, prices of 
generics in a number of European countries are based on pre-patent loss prices. This is in line 
with previous studies [39,40,64]. We would again expect to find considerable differences in 
the prices of generic risperidone between countries, because of the different pricing initiatives 
and differences in the attractiveness in the generic market [1,38,39,62,64,67]. 
Finally, we calculated the influence of the availability of generic risperidone on subsequent 
atypical antipsychotic expenditure where possible. 
No ethics approval was needed or obtained because only aggregated drug utilisation data was 
used, without access to specific patient data. 
Results 
There was a consistent steady reduction in the utilisation of risperidone as a percentage of 
total selected atypical utilisation in all the four countries over time following the introduction 
of generic risperidone (Figure 1). 
Figure 1 Percentage utilisation of risperidone (defined daily dose (DDD) basis) versus 
selected atypical antipsychotic drugs in selected European countries. 
There were significant differences in the rate of utilisation of risperidone between the four 
countries before generic risperidone was launched (Table 1, initial slope). However, there 
was less variation in the utilisation of risperidone between the four European countries after 
generic drugs became available (Figure 1, Table 1). The average decline in the percentage of 
risperidone versus the other selected atypical antipsychotic drugs persisted after generic 
risperidone was introduced but to a lesser extent, with an initial average drop of −0.0774 and 
a change in slope from −0.144% to −0.00548% per month (Table 1). However, this combined 
change in the slope after month 0 was not statistically significant. 
Table 1 Characteristics of the utilisation of risperidone after generic availability (month 
zero) 
Consolidated atypical antipsychotics following generic risperidone 
 Coefficient value (95% CI) P-value 
Initial intercept 22.70 (18.58 to 26.82) <0.001 
Change in intercept at month 0 −0.0774 (−1.080 to 0.925) 0.880 
Initial slope −0.144 (−0.158 to -0130) <0.001 
Change in slope after month 0 −0.00548 (−0.0545 to 0.0436) 0.827 
There was variation between the four countries in the rate of decline in the utilisation of 
risperidone after the introduction of generic risperidone (month 0). Sweden had the fastest 
decline, while Scotland, already having the lowest levels of risperidone utilisation, had the 
slowest decline (Table 2). However when combined, there was no statistically significant 
change in risperidone utilisation patterns following the introduction of generics (Table 1). 
There was also no significant change in the utilisation of risperidone after the introduction of 
generic risperidone in separate single country studies conducted in Belgium, Scotland and 
Sweden [46,48,56]. 
Table 2 Slope of risperidone utilisation between the four European countries after 
generic risperidone became available (month 0) 
Country Slopea 
Belgium −0.165 
Ireland −0.143 
Scotland −0.075 
Sweden −0.194 
aA slope of −0.165 = a drop of 0.165%/ month in the utilisation of risperidone as a percenage of all selected 
atypical antipsychotics following introduction of generic risperidone. 
A similar pattern was also seen in Austria (Table 3) and Spain (Catalonia) (Figure 2). In 
Spain, utilisation of risperidone declined from 35% of selected atypical antipsychotic drugs in 
2006 (DDD basis) to 28% by the third quarter of 2011 (Figure 2). 
Table 3 Utilisation of selected atypical antipsychotics in Austria as a percentage of total 
atypical antipsychotic use between 2005 and 2010 (defined daily dose basis) 
Atypical antipsychotic 2005 2006 2007 2008 2009 2010 % Change 
Risperidone 31.6 29.9 28.6 26.9 25.5 23.8 -25 
Amisulpride 8.4 7.1 6.7 6.3 5.9 5.5 -35 
Aripiprazole 2.5 5.4 7.2 9.1 10.6 11.8 376 
Olanzapine 36.6 33.3 31.3 29.6 28.0 26.1 -29 
Quetiapine 18.6 22.5 24.8 27.0 29.6 32.7 75 
Paliperidone 0.00 0.00 0.00 0.02 0.04 0.03 NA 
Zotpine 2.2 1.8 1.4 0.9 0.4 0.1  
NA, not available. 
Figure 2 Utilisation of selected atypical antipsychotic drugs in Catalonia, Spain, in 
(defined daily dose (DDD) on a quarterly basis from January 2006 to end of September 
2011. 
In Bury PCT, the prescribing of risperidone averaged between 16% and 21% of the selected 
atypical antipsychotics dispensed between November 2009 and October 2011 (Figure 3). 
However, there was no recognised pattern to the prescribing of risperidone, with its 
utilisation varying randomly between the months. Again, utilisation of selected atypical 
antipsychotic drugs was dominated by olanzapine and quetiapine. 
Figure 3 Utilisation of atypical antipsychotic drugs in Bury Primary Care Trust (PCT) 
November 2009 to October 2011. 
There was variation between the various European countries and regions in the utilisation of 
long-acting risperidone injections as a percentage of total risperidone. This ranged from an 
average of 6% to 7% in Scotland to 18.5% to 20% in Sweden, and over 20% in Belgium, 
before reducing in later months in Belgium following tightening of the prescribing 
regulations versus oral risperidone [48]. There was generally low utilisation of paliperidone 
in all the countries and regions studied (Table 4), despite paliperiodone being available before 
oral generic risperidone in the four principal countries. 
Table 4 Maximum utilisation of paliperidone (oral and injectable) as a percentage of 
total selected antipsychotic utilisation in the various European countries and regions 
Country Paliperidone (maximum), % 
Austria 0.04 
Belgium 4.8 
Bury PCT 0.07 
Ireland (GMS population) 1.01 
Scotland 0.03 
Spain (Catalonia) 3.99 
Sweden 1.5 
GMS - General Medical Services. 
There was also considerable variation in the utilisation of oral generic versus originator 
risperidone by the end of the study period in each of the four principal countries (Table 5). 
Similarly, there was considerable variation between the four countries in the price reduction 
of oral generic risperidone (expenditure/DDD) versus pre-patent loss prices by the end of the 
study period. 
  
Table 5 Percentage utilisation of oral generic risperidone versus total risperidone (DDD 
basis) and percentage reduction in expenditure per defined daily dose for oral generic 
risperidone versus pre-patent loss prices by the end of the study period in each country 
Country Utilisation of generic risperidone, % Price reduction, % 
Belgium 52 59 
Ireland 14 28 
Scotland 98 84 
Sweden 96 80 
In both Scotland and Sweden, the high utilisation of generic risperidone at low prices (Table 
5) resulted in expenditure for atypical antipsychotic drugs increasing at a lower rate than 
utilisation. Utilisation of the selected atypical antipsychotic drugs in Scotland increased by 
53% between 2005 and 2010, but expenditure increased by only 42%. In Sweden, utilisation 
increased by 20% after the introduction of oral generic risperidone until August 2011, with 
expenditure increasing by only 13%. 
Discussion 
As expected, there was no increase in the utilisation of risperidone compared with the other 
atypical antipsychotic drugs after the introduction of generic risperidone in either Belgium, 
Ireland, Scotland or Sweden (Figure 1), or in Bury PCT (Figure 3). In fact, if anything the 
reverse was seen, with increased prescribing of patented atypical antipsychotics in the four 
countries (Figure 1). A similar picture was also seen in Austria and Spain (Table 3; Figure 2) 
with generic extended release (ER) quetiapine not being available in Spain until near the end 
of the study. However, there were significant differences in the rate of decline in risperidone 
utilisation between the four countries before generic risperidone was launched (Table 1). 
However, there was less variation in the rate of decline after generic risperidone became 
available (Figure 1; Table 1), with the combined decline in risperidone utilisation falling to 
−0.00548% per month from −0.144% per month (Table 1). The rate of decline was greater in 
Sweden than Scotland (Table 2). However, there was overall a reasonable consistency 
between the four countries, irrespective of their characteristics [39,68], reflected by the lack 
of a statistically significant change in slope after month 0 (Table 1). This was also no 
statistically significant difference in the rate of risperidone utilisation after generic 
risperidone became available in the separate analyses conducted in Belgium, Scotland and 
Sweden [46,48,56]. 
The consistent findings between the seven European countries and regions, including Austria 
(Table 3), Spain (Figure 2) and Bury PCT (Figure 3), regarding risperidone utilisation 
following the introduction of generics would suggest that following generic availability, there 
was no increased prescribing of oral risperidone for new patients, for whom risperidone could 
be one of the treatment options. However, we cannot say this with certainty without analysing 
patient-specific data. No increased prescribing of risperidone following introduction of 
generics (Figures 1, 2 and 3; Tables 1 and 3) may reflect the advice from organisations such 
as the National Institute for Health and Care Excellence in the UK and from various 
published studies that treatment of patients with schizophrenia should be individualised to 
maximise patient outcomes [17-19,69,70]. The growing utilisation of the other atypical 
antipsychotics, especially quetiapine and aripiprazole, in the various countries following the 
introduction of generic risperidone (Figures 1 and 2; Table 3) may reflect the marketing 
activities of the manufacturers of patented atypical antipsychotic drugs including ER 
quetiapine in Spain, influencing the choice of antipsychotic drug prescribed [46,48,71-73]. 
However, it is more likely to reflect the recognised weight neutrality with aripiprazole versus 
olanzapine and risperidone, as well as the effectiveness of aripiprazole and quetiapine ER in 
treating patients with major depressive disorders who have had an incomplete response to 
antidepressants, and of quetiapine ER in treating patients with bipolar depression [74-76], 
given the limited utilisation of patented paliperidone in recent years (Table 4). However, this 
remains to be elucidated in further research. There was also no substantial increase in the 
utilisation of long-acting risperidone in the four principal countries following the introduction 
of oral generic risperidone. If anything, the reverse was seen in Belgium in recent years, as 
reimbursement is denied if the medical adviser appointed by the patient’s insurer is not 
satisfied with the rationale provided by the physician [48]. 
The findings also potentially suggest there is no ‘spillover’ or cross-transfer of learning in 
practice from one disease area to another to produce changes in physician prescribing habits, 
that is, no crossover of learning to increase the prescribing of generics when available as seen 
with the PPIs, renin-angiotensin inhibitor drugs and statins [1,38-41,43-45,59,77]. We believe 
this is an important finding from this research. However, this finding is tempered by the 
recognised need to tailor pharmacological treatment for patients with schizophrenia or bipolar 
disease, especially with regard to issues such as weight gain and effectiveness in different 
patient populations, as well as reluctance among physicians to switch treatments when 
patients are stable on a particular atypical antipsychotic drug. 
We believe a second important finding is that in some disease areas it is difficult for health 
authorities to encourage the preferential prescribing of multiple sourced versus patented 
drugs, apart from introducing measures such as prescribing restrictions for different 
formulations of a molecule [48]. This illustrated by limited initiatives by any of the seven 
countries and regions to enhance the prescribing of oral risperidone following the 
introduction of generics. This is unlike the situation for the PPIs, renin-angiotensin inhibitor 
drugs and the statins [1,38,40,42,77]. We believe, based on our findings (especially those 
from Bury PCT following its activities (Figure 3) when recently it was very successful in 
significantly enhancing the prescribing of generic losartan versus patented ARBs (angiotensin 
receptor blocker) for treating hypertension with multiple demand-side measures [59]), that 
the influence of measures such as prescribing guidance or guidelines highlighting the 
preferential prescribing of generic atypical antipsychotic drugs as first line treatments may be 
limited. This is especially the case if there is a good clinical rationale for prescribing a 
patented product including concerns with weight gain. Additional measures could include 
instigating reimbursement restrictions for oral patented atypical antipsychotics, which is 
similar to the situation for long-acting risperidone injections in Austria and Belgium [47,48]. 
However, such measures may again be difficult to implement, given the subjective nature of 
choosing pharmacological treatment options to maximise patient outcomes in these complex 
disease areas, and may even be counterproductive. 
The considerable variation between European countries in the prescribing of oral generic 
risperidone versus originators (Table 5) reflects the different policies in these countries to 
encourage use of generics. The high rates seen in Scotland and Sweden suggest that there are 
no problems with generic risperidone in clinical practice. This is no doubt enhanced by the 
strict regulations for granting marketing authorisation for generics in Europe, with authorities 
removing generic products where concerns exist [63,64,78]. Consequently, the differences 
are down to different demand-side measures between the four countries. The high utilisation 
of oral generic risperidone in Scotland reflects generally high voluntary INN (International 
Non-proprietary Name) prescribing rates across classes. This starts with extensive physician 
education in medical school to prescribe by INN, which is followed up in ambulatory care 
through pharmacists working for the Health Boards monitoring the prescribing of drugs 
[40,46,49]. The high rates in Sweden reflect the instigation of compulsory generic 
substitution, including risperidone, apart from in a limited number of cases 
[39,40,56,77,79,80]. We believe the high voluntary INN prescribing rates in the UK provides 
guidance to other countries. This is because such activities reduce patient confusion once 
multiple sources become available, especially if patients are dispensed different branded 
generics with different names on each occasion, without adequate explanation. This can 
happen in Sweden with compulsory generic substitution, apart from a limited number of 
situations authorised by the Medicine Product Agency [81], and more recently with monthly 
auctions as the cheapest branded generic secures an appreciable proportion of prescriptions 
for the molecule the following month [1,38]. The dispensing of different branded generics on 
each occasion can possibly cause confusion and concern if patients do not receive adequate 
information about their medicines [82]. This can potentially result in either duplication of 
medicines, or alternatively, in patients not taking their prescribed treatments as directed, 
which could be problematic [82,83]. INN prescribing, apart from a limited number of well-
known situations, is one way to address this [49,80,84,85]. 
There were also appreciable differences between countries concerning the price of generic 
risperidone (Table 4). This reflects the different policies between the four countries with 
regard to enhancing the utilisation of generics, as well as their different pricing policies. The 
considerable price reduction for generic risperidone in Scotland, which is similar to those for 
other generics, follows recent reforms in the UK to enhance transparency in the cost of 
producing generics, as well as discounts offered by manufacturers to wholesalers and 
pharmacists to preferentially dispense their generic [41,49]. The price reduction in Sweden, 
which is also similar to those for other generics, is a result of the introduction of compulsory 
generic substitution with the lowest priced molecule [1,38,80]. Generic prices are likely to 
fall further in Sweden with the recent introduction of monthly auctions, with the 
manufacturer who wins the auction being guaranteed a considerable proportion of dispensed 
generics the following month [1,38]. The more modest price reduction for generic risperidone 
in Belgium reflects the current situation, where generic companies only have to lower their 
prices to the reference price level to be reimbursed. This was only 16% versus pre-patent loss 
prices until 2002, 20% until 2003, 26% until 2005, and is currently 31% [48,68,85]. The high 
prices for generics in Ireland reflect the limited measures to date to reduce these, although 
this is now changing [39,86]. These findings are consistent with other research showing that 
the lowest prices for generics in Europe are seen in countries with the greatest market share 
[62,63,67]. Consequently, measures to increase the attractiveness of the generic market, as 
well as enhance the transparency in their pricing, as seen in Sweden and the UK, provide 
guidance to countries seeking ways to achieve further savings from the use of generics. This 
is especially the case where it is difficult to encourage the preferential prescribing of generics 
versus patented products, for example, atypical antipsychotic drugs. 
We are aware there are a number of limitations with this study. This includes no access to 
patient data to assess whether there has been an increase in the prescribing of risperidone as 
first line treatment since the introduction of generics. In addition, there is no knowledge of 
the prescribed indications, especially with risperidone being the only atypical antipsychotic 
drug currently licensed for asymptomatic treatment in patients with dementia. However, the 
consistent continued decline in the utilisation of risperidone following the introduction of 
generics, coupled with increased utilisation of patented atypical antipsychotic drugs (Figures 
1 and 2; Table 3), suggests there has been no increase in the prescribing of risperidone 
following generics. This may be enhanced by increased awareness of the lack of effect on 
weight with aripiprazole, and the effectiveness of aripiprazole and quetiapine ER in major 
depressive disorders. We have also not assessed whether there are any differences in 
outcomes between oral generic and originator risperidone. Previous research findings and the 
continued high utilisation of generic risperidone in Scotland and Sweden (Table 5) suggest 
there are no problems with generic atypical antipsychotic drugs in clinical practice 
[6,46,49,50,87]. However, again, we cannot say this with certainty without specific patient 
research. Finally, we are unable to determine or comment on the extent of any polypharmacy 
with atypical antipsychotic drugs. 
Conclusions 
Generics provide a considerable opportunity for authorities to fund increased drug volumes 
and new premium-priced drugs within available resources. However, there are disorders such 
as schizophrenia for which it is difficult to encourage the preferential prescribing of multiply 
sourced drugs as first line treatments. This is due to the recognised need to tailor 
pharmacological treatments to the individual patient in order to maximise outcomes. This 
belief has resulted in limited demand-side measures by the seven European countries and 
regions to encourage the preferential prescribing of generic versus patented atypical 
antipsychotic drugs, compared with the multiple measures generally instigated for the PPIs 
and statins following introduction of generics. We have also shown that authorities across 
Europe cannot rely on the transfer of learning concerning the prescribing of generics as first 
line treatment from one class to another in order to affect changes in the prescribing habits of 
atypical antipsychotic drugs. This is no doubt enhanced in this case by the need to tailor 
treatments and the heterogeneity of the products in the class. However, we believe that any 
demand-side initiatives, apart from encouraging one dosage form over another, would have 
only a limited effect, owing to the complexity of treating patients with schizophrenia or 
bipolar disease, and the recognised differences in side-effect profiles between the various 
pharmacological approaches. Consequently, we do not believe the authorities in any of the 
seven countries or regions studied are planning specific measures in the future. This decision 
is no doubt helped by more oral atypical antipsychotic drugs now being available as multiple 
sourced products, helping to lower overall drug acquisition costs. 
Finally, we believe countries can learn from each other regarding potential additional ways to 
further enhance the prescribing of generic versus originator atypical antipsychotic drugs, and 
to obtain lower prices where pertinent. This includes measures such as increasing INN 
prescribing and greater transparency in the pricing of generics. 
  
Box 1 – Administrative databases used in the study [39-41,46-
48,56,59,68,86,88] 
• Austria: Internal data warehouse of the HVB (Hauptverband der Österreichischen 
Sozialversicherungsträger) – BIG – coupled with Cube HMSTAT, based on the ‘Maschinelle 
Heilmittelabrechnung’. This provides reimbursement data on medicines dispensed in 
ambulatory care in approximately 98% of the Austrian population. 
• Belgium: Pharmanet, a database of reimbursed medicines dispensed in ambulatory care in 
Belgium. This database is maintained by the National Institute for Health and Disability 
Insurance and covers the whole Belgian population. 
• England (Bury PCT): National Health Service Business Services Division prescription 
pricing database (ePACT). 
• Ireland: the National Shared Services Primary Care Reimbursement Service of the Health 
Service Executive in Ireland (HSE-PCRS) pharmacy claims database. This database provides 
details on monthly dispensed medications for each individual within the GMS population. 
The GMS population covers approximately 30% of the population of Ireland with higher 
morbidity than the general population, which is reflected in their consumption of 
approximately 65% of total pharmaceutical expenditure in Ireland. 
• Scotland: NHS National Services Scotland Corporate Warehouse, covering the entire 
population in Scotland. 
• Spain (Catalonia):DMART (Catalan Health Service) database, covering the public system in 
Catalonia. 
• Sweden: National Swedish Pharmacy Register covering the entire Swedish population. 
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